Anti-Borrelia Select ELISA (IgM)

- **Based on highly specific, recombinant Borrelia antigens, including dimeric OspC advanced**
- **Significantly reduced cross reactivity compared to whole antigen tests**
- **Simple and fast test performance – fully automatable**

Technical data

Antigen	Specific, recombinant antigens from different human pathogenic Borrelia strains, including dimeric OspC advanced
Calibration	Quantitative, in relative units per milliliter (RU/ml)
	Calibrator 1: 200 RU/ml
	Calibrator 2: 20 RU/ml
	Calibrator 3: 2 RU/ml
	Recommended upper limit for non-infected individuals (cut-off): 20 RU/ml
Sample dilution	Serum or plasma; 1 : 101 in sample buffer
Reagents	Ready for use, with the exception of the wash buffer (10x), colour-coded solutions, largely exchangeable with those in other EUROIMMUN ELISA kits.
Test procedure	60 min (37 °C) / 30 min / 15 min (room temperature), fully automatable
Measurement	450 nm, reference wavelength between 620 nm and 650 nm
Test kit format	96 break-off wells, kit includes all necessary reagents
Order No.	**EI 2132-9601-5 M**

Clinical significance

Borrelia are the causative agent of Lyme borreliosis, a bacterial disease which is transmitted through bites from ticks of the genus Ixodes. The most important human pathogenic Borrelia genospecies are B. afzelii, B. burgdorferi and B. garinii. Lyme borreliosis can manifest itself dermatologically, neurologically or through internal disorders. The radially spreading erythema migrans is a characteristic early symptom, which occurs a few days to several weeks after the infection. This is often accompanied by influenza-like general symptoms, such as fever, shivering, headaches and vomiting. The advanced stage of the disease is characterised by neurological (e.g. facial paresis), cardiac (e.g. myocarditis) and rheumatological (e.g. arthritis) manifestations. In chronic Lyme borreliosis involvement of the joints, epidermis (acrodermatitis chronica atrophicans) and central nervous system as well as fatigue are typically found. For the serological diagnosis of anti-Borrelia-specific antibodies, the German Association for Hygiene and Microbiology (DGHM), the Robert Koch Institute and the CDC (Atlanta, Georgia) call for a two-stage strategy. Firstly, a sensitive screening test (ELISA or IIFT) is performed. Sera with a positive or borderline screening result are investigated further using an immunoblot to differentiate between Borrelia-specific and unspecific reactions.

Diagnostic application

The Anti-Borrelia Select ELISA (IgM) is based on a mixture of highly specific recombinant antigens of different human pathogenic Borrelia strains. The most important antigen component included in the test is covalently bound, dimeric OspC (OspC advanced, European patent application, EP 2 199 303 A1), which was optimised for the use in the ELISA. OspC advanced has a more than 30% higher specificity than conventional recombinant OspC (Probst et al., ICLB, 2010). The Anti-Borrelia Select ELISA (IgM) shows far less cross reactivity than a lysate-based ELISA, e.g. in patients with autoimmune or other diseases. With its specifically composed antigen mixture, the Anti-Borrelia Select ELISA (IgM) provides a high sensitivity and is therefore ideally suited for use as a screening test.

Autoimmune diagnostics	Infection diagnostics	Allergy diagnostics	Antigen detection	Molecular genetic diagnostics	Automation

Reference range

The prevalence of Borrelia-specific IgM antibodies was determined by investigating in a panel of 500 healthy blood donors (Medical University of Lübeck), using the EUROIMMUN Anti-Borrelia Select ELISA (IgM). At a cut-off of 20 RU/ml, 2.8% of the donors were seropositive.

Reproducibility

The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation (CV) using 3 sera with values at different points on the calibration curve. The intra-assay CVs is based on 20 determinations, the inter-assay CVs on 4 determinations in 6 different test runs.

Serum	Intra-assay variation, n = 20		Inter-assay variation, n = 4 x 6	
	Mean value (RU/ml)	CV (%)	Mean value (RU/ml)	CV (%)
1	28	7.0	31	11.7
2	55	5.8	55	7.6
3	56	2.9	111	4.7

Agreement with quality assessment results

73 samples from quality assessment scheme providers (INSTAND e.V., Germany; EQUALIS, Sweden; IQS, Germany; Labquality, Finland and RfB, Germany) were investigated with the EUROIMMUN Anti-Borrelia Select ELISA (IgM). The agreement of the qualitative ELISA results with the specifications of the quality assessment institutes was 99% (excluding borderline sera).

n = 73		Specifications of the quality assessment		
		positive	borderline	negative
EUROIMMUN Anti-Borrelia Select ELISA (IgM)	positive	19	0	1
	borderline	0	1	1
	negative	2	1	48

Test results with respect to critical sera

Owing to the selection of highly specific recombinant antigens of human pathogen Borrelia strains, the Anti-Borrelia Select ELISA (IgM) shows significantly lower cross reactivity in comparison to a lysate-based test (e.g. Anti-Borrelia-ELISA (IgM)). The number of positive findings in patients with Treponema pallidum infection or autoimmune diseases was significantly lower when the investigation was performed using the Anti-Borrelia Select ELISA (IgM).

Panel	n	Anti-Borrelia IgM results ≥20 RU/ml (cut-off) with respect to EUROIMMUN	
		Anti-Borrelia ELISA (IgM)	Anti-Borrelia Select ELISA (IgM)
Anti-Treponema pallidum strong-positive sera	92	26 (28.3%)	6 (6.5%)
Autoimmune diseases	27	7 (25.9%)	1 (3.7%)

Clinical data

33 sera from patients with clinically characterised early stage Lyme borreliosis (Erythema migrans) were investigated with the Anti-Borrelia Select ELISA (IgG, IgM), Anti-Borrelia-plus-VlsE ELISA (IgG) and Anti-Borrelia ELISA (IgM). In the parallel determination of IgG and IgM antibodies, the Anti-Borrelia Select ELISA (IgG, IgM) showed the same sensitivity (91%) as the tests based on lysate.

Test system*	ELISA results (n = 33)	
	IgG or IgM	IgG plus IgM
Anti-Borrelia Select ELISA (IgG)	21 (63.6%)	30 (91%)
Anti-Borrelia Select ELISA (IgM)	22 (66.7%)	
Anti-Borrelia-plus-VlsE ELISA (IgG)	27 (81.8%)	30 (91%)
Anti-Borrelia ELISA (IgM)	25 (75.8%)	

*Cut-off, ≥20 RU/ml

Literature

1. Lawrenz MB, Hardham JM, Owens RT, Nowakowski J, Steere C, Wormser CP, Norris SJ. Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi. J Clin Microbiol. 1999 Dec;37(12):3997-4004.
2. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of lyme borreliosis. Clin Microbiol Rev. 2005 Jul;18(3):484-509.
3. Wilske B, Fingerle V, Schulte-Spechtel U. Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol. 2007 Feb;49(1):13-21.
4. Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, Kristoferisch W, O'Connell S, Ornstein K, Strle F, Gray J. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011 Jan;17(1):69-79.
5. Probst C, Ott A, Scheper T, Meyer W, Stöcker W, Komorowski L. N-terminal disulfide-bridging of Borrelia outer surface protein C increases its diagnostic and vaccine potentials. Ticks Tick Borne Dis. 2012 Feb;3(1):1-7.

Autoimmune diagnostics	Infection diagnostics	Allergy diagnostics	Antigen detection	Molecular genetic diagnostics	Automation